Photo: streetinsider.com
Anteris Launches Pivotal Trial for Innovative Heart Valve Device
Anteris Technologies has initiated a pivotal trial for its innovative DurAVR Transcatheter Heart Valve system, aiming to address aortic stenosis with promising new technology.
- The PARADIGM Trial, a randomized controlled trial, has commenced with the first patients treated at The Heart Center, Rigshospitalet in Copenhagen, Denmark.
- Anteris Technologies, listed on both Nasdaq and the Australian Securities Exchange, is evaluating the safety and efficacy of the DurAVR THV against existing treatments.
- The DurAVR Transcatheter Heart Valve system is designed to provide a less invasive solution for patients suffering from aortic stenosis, a common heart valve disease.
Why It Matters
This trial represents a significant advancement in heart valve replacement technology, potentially improving treatment options for patients with aortic stenosis. The success of Anteris Technologies could influence the future of medical device innovations in cardiology.